(VBK) VERBIO Vereinigte BioEnergie - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0JL9W6
Stock: Biodiesel, Bioethanol, Biomethane, Glycerine, Fertilizer
Total Rating 54
Risk 67
Buy Signal 0.07
| Risk 5d forecast | |
|---|---|
| Volatility | 60.8% |
| Relative Tail Risk | -10.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.84 |
| Alpha | 155.02 |
| Character TTM | |
|---|---|
| Beta | 0.463 |
| Beta Downside | 0.855 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.35% |
| CAGR/Max DD | -0.24 |
EPS (Earnings per Share)
Revenue
Description: VBK VERBIO Vereinigte BioEnergie February 22, 2026
Verbio SE (ticker: VBK) is a German-based producer and distributor of bio-fuels and bio-based chemicals, operating across Biodiesel, Bioethanol/Biomethane, and ancillary segments. Its portfolio includes biodiesel, bioethanol, biomethane, pharma-grade glycerine, olefin metathesis catalysts, animal feeds, phytosterols, and fertilizers, serving industries from energy utilities to cosmetics and agriculture.
Recent figures show Verbio generated €1.32 billion in revenue for FY 2024, with an adjusted EBITDA margin of 8.5% and a 12% increase in biodiesel output capacity to 1.2 Mt per year. The company benefits from the EU Renewable Energy Directive’s stricter bio-fuel blending targets and a growing demand for sustainable aviation fuel, which together are projected to lift European bio-fuel consumption by ~15% annually through 2028.
For deeper insight, explore ValueRay’s detailed analysis.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -112.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -0.55 > 1.0 |
| NWC/Revenue: 13.28% < 20% (prev 20.00%; Δ -6.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 43.3m > Net Income -112.2m |
| Net Debt (215.7m) to EBITDA (47.2m): 4.57 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.6m) vs 12m ago 14.19% < -2% |
| Gross Margin: 6.98% > 18% (prev 0.16%; Δ 682.8% > 0.5%) |
| Asset Turnover: 128.8% > 50% (prev 107.5%; Δ 21.25% > 0%) |
| Interest Coverage Ratio: -4.79 > 6 (EBITDA TTM 47.2m / Interest Expense TTM 18.0m) |
Altman Z'' 1.76
| A: 0.18 (Total Current Assets 532.2m - Total Current Liabilities 303.4m) / Total Assets 1.28b |
| B: 0.15 (Retained Earnings 197.0m / Total Assets 1.28b) |
| C: -0.06 (EBIT TTM -86.4m / Avg Total Assets 1.34b) |
| D: 0.49 (Book Value of Equity 260.7m / Total Liabilities 533.3m) |
| Altman-Z'' Score: 1.76 = BBB |
Beneish M -2.40
| DSRI: 1.02 (Receivables 106.5m/91.5m, Revenue 1.72b/1.50b) |
| GMI: 2.23 (GM 6.98% / 15.55%) |
| AQI: 0.20 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 1.15 (Revenue 1.72b / 1.50b) |
| TATA: -0.12 (NI -112.2m - CFO 43.3m) / TA 1.28b) |
| Beneish M-Score: -2.40 (Cap -4..+1) = BBB |
What is the price of VBK shares?
As of February 22, 2026, the stock is trading at EUR 24.20 with a total of 72,402 shares traded.
Over the past week, the price has changed by -0.17%, over one month by +2.11%, over three months by +50.97% and over the past year by +160.92%.
Over the past week, the price has changed by -0.17%, over one month by +2.11%, over three months by +50.97% and over the past year by +160.92%.
Is VBK a buy, sell or hold?
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.7 | -39.4% |
| Analysts Target Price | - | - |
VBK Fundamental Data Overview February 21, 2026
Market Cap USD = 1.31b (1.12b EUR * 1.1789 EUR.USD)
P/S = 0.9203
P/B = 2.0862
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.18% (E(1.12b)/V(1.40b) * Re(7.62%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
Fair Price DCF = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%
P/S = 0.9203
P/B = 2.0862
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.18% (E(1.12b)/V(1.40b) * Re(7.62%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
Fair Price DCF = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%